Cargando…

Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization

Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInform...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönharting, Wolfgang, Roehnisch, Tim, Manoochehri, Mehdi, Christoph, Jan, Sieger, Marie, Nogueira, Mauro, Martos-Contreras, Mari Carmen, Kunz, Meik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301538/
https://www.ncbi.nlm.nih.gov/pubmed/37376412
http://dx.doi.org/10.3390/vaccines11061023
_version_ 1785064835346595840
author Schönharting, Wolfgang
Roehnisch, Tim
Manoochehri, Mehdi
Christoph, Jan
Sieger, Marie
Nogueira, Mauro
Martos-Contreras, Mari Carmen
Kunz, Meik
author_facet Schönharting, Wolfgang
Roehnisch, Tim
Manoochehri, Mehdi
Christoph, Jan
Sieger, Marie
Nogueira, Mauro
Martos-Contreras, Mari Carmen
Kunz, Meik
author_sort Schönharting, Wolfgang
collection PubMed
description Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer.
format Online
Article
Text
id pubmed-10301538
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103015382023-06-29 Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization Schönharting, Wolfgang Roehnisch, Tim Manoochehri, Mehdi Christoph, Jan Sieger, Marie Nogueira, Mauro Martos-Contreras, Mari Carmen Kunz, Meik Vaccines (Basel) Case Report Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer. MDPI 2023-05-25 /pmc/articles/PMC10301538/ /pubmed/37376412 http://dx.doi.org/10.3390/vaccines11061023 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Schönharting, Wolfgang
Roehnisch, Tim
Manoochehri, Mehdi
Christoph, Jan
Sieger, Marie
Nogueira, Mauro
Martos-Contreras, Mari Carmen
Kunz, Meik
Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title_full Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title_fullStr Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title_full_unstemmed Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title_short Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
title_sort improved survival of a her2-positive metastatic breast cancer patient following a personalized peptide immunization
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301538/
https://www.ncbi.nlm.nih.gov/pubmed/37376412
http://dx.doi.org/10.3390/vaccines11061023
work_keys_str_mv AT schonhartingwolfgang improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT roehnischtim improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT manoochehrimehdi improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT christophjan improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT siegermarie improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT nogueiramauro improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT martoscontrerasmaricarmen improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization
AT kunzmeik improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization